BioWorld MedTech

March 26, 2013

Deals roundup: Argon to acquire Angiotech interventional unit for $362M

In a move to perhaps eliminate a significant portion of its debt, Angiotech Pharmaceuticals (Vancouver, British Columbia) reported the sale of its interventional products business to Argon Medical Devices (Plano, Texas) for $362.5 million. Read More

Third Rock raises $516M in oversubscribed Fund III

Financings roundup: Bausch + Lomb files IPO registration statement

Washington roundup: FDA warning to Stryker offers no insight into Neptune recall

International report: Stereotaxis receives regulatory approval of Niobe tech in Japan

Agreements/contracts: Aerocrine, Medisoft agree to licensing settlement terms

Court report: BCBSM files motion to dismiss antitrust lawsuit filed against it

Grants roundup: Stanford pediatric cancer study receives funding

Med-Tech Notes

Product Briefs

People in the News

MDD's Cardio Extra

Today's news in brief

BioWorld

BioWorld briefs for Jan. 13, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for January 13, 2025

Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal

BioWorld

The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...

Proteomics study explores how protein changes influence disease

BioWorld Science

Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...

Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance

BioWorld

Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...